The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis c virus genotype 1 infection without cirrhosis

Gastroenterology

Volumn 147, Issue 2, 2014, Pages

  Manns, Michael P ^a,i   Vierling, John M ^b   Bacon, Bruce R ^c   Bruno, Savino ^d   Shibolet, Oren ^e   Baruch, Yaacov ^f   Marcellin, Patrick ^g   Caro, Luzelena ^h   Howe, Anita Y M ^h   Fandozzi, Christine ^h   Gress, Jacqueline ^h   Gilbert, Christopher L ^h   Shaw, Peter M ^h   Cooreman, Michael P ^h   Robertson, Michael N ^h   Hwang, Peggy ^h   Dutko, Frank J ^h   Wahl, Janice ^h   Mobashery, Niloufar ^h  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d FATEBENEFRATELLI HOSPITAL   (Italy)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f Liver Unit   (Israel)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Chronic HCV; Protease Inhibitor; Response Guided Therapy; Sustained Virologic Response

Indexed keywords

AMINOTRANSFERASE; BOCEPREVIR; HEMOGLOBIN; MK 5172; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHILL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; EVENING DOSAGE; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

CHRONIC HCV; PROTEASE INHIBITOR; RESPONSE-GUIDED THERAPY; SUSTAINED VIROLOGIC RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROLINE; QUINOXALINES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904708963     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.04.006     Document Type: Article

References (24)

1. M.P. Manns, and T. von Hahn Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 12 2013 595 610
2. M.P. Manns, G.R. Foster, and J.K. Rockstroh et al. The way forward in HCV treatment-finding the right path Nat Rev Drug Discov 6 2007 991 1000
3. M.P. Manns, J.G. McHutchison, and S.C. Gordon et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
4. M.W. Fried, M.L. Shiffman, and K.R. Reddy et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
5. B.L. Pearlman, and N. Traub Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more Clin Infect Dis 52 2011 889 900
6. M.G. Swain, M.Y. Lai, and M.L. Shiffman et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin Gastroenterology 139 2010 1593 1601
7. M.P. Manns, P.J. Pockros, and G. Norkrans et al. Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin J Viral Hepat 20 2013 524 529
8. F. Poordad, B. Bacon, and S. Bruno et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
9. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
10. B. Bacon, S. Gordon, and E. Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
11. S. Zeuzem, P. Andreone, and S. Pol et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
12. I. Jacobson, E. Yoshida, and M. Sulkowski et al. Treatment with sofosbuvir + ribavirin for 12 weeks achieves SVR12 of 78% in GT2/3 interferon-ineligible, -intolerant, or -unwilling patients: results of the phase 3 Positron trial J Hepatol 58 2013 S28
13. M. Manns, P. Marcellin, and F. Poordad et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from Quest-2 a phase III trial J Hepatol 58 2013 S568
14. P. Ferenci, T. Asselah, and G. Fosters et al. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from Startverso1, a randomised, double-blind, placebo-controlled phase II trial J Hepatol 58 2013 S569
15. A. Petry, I. Fraser, and E. O'Mara et al. Safety and antiviral activity of MK-5172, a next generation HCV NS3/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV infected patients Hepatology 54 2011 531A
16. V. Summa, S.W. Ludmerer, and J.A. McCauley et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
17. L. Caro, L. Du, and S. Huang et al. Relationship between transaminase levels and plasma pharmacokinetics following administration of MK-5172 with pegylated interferon alfa-2b and ribavirin to HCV genotype G1 treatment-naive patients J Hepatol 58 2013 S328
18. D. Iusuf, S.E. van de, and A.H. Schinkel Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification Clin Pharmacol Ther 92 2012 559 562
19. K.V. Kowdley, E. Lawitz, and I. Crespo et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Lancet 381 2013 2100 2107
20. M.S. Sulkowski, T. Asselah, and J. Lalezari et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial Hepatology 57 2013 2143 2154
21. M.W. Fried, M. Buti, and G.J. Dore et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
22. F. Lahser, R. Liu, and K. Bystol et al. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in vitro in HCV replicons Hepatology 56 2012 236A
23. D.J. Graham, A. Acosta, and Z. Guo et al. MK-5172, a second generation HCV NS3/4A protease inhibitor is active against common resistance associated variants (RAVS) and exhibits cross-genotype activity Hepatology 54 2011 139A
24. E. Lawitz, J. Vierling, and A. Murillo et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY study Hepatology 58 2013 244A 245A